Isolation and Characterization of Three Antihypertension Peptides from the Mycelia of <i>Ganoderma Lucidum</i> (Agaricomycetes)

Wu, Qiang; Li, Yong; Peng, Kuan; Wang, Xiaoling; Ding, Zhongyang; Li, Liming; Xu, Peng; Liu, Gao-Qiang

doi:10.1021/acs.jafc.9b02276

Cited by 67 publications

(43 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…QLVP can inhibit ACE by its interaction with Gln242 and Lys472 of ACE. QLVP also enhanced Angiotensin 1-mediated phosphorylation of eNOS and reduced mRNA and protein expression of the vasoconstrictor peptide endothelin-1 in HUVECs (Wu et al, 2019).…”

Section: G Lucidum At the Bench: Mechanism Of Action In Cvdsmentioning

confidence: 90%

See 1 more Smart Citation

Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety

et al. 2020

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are a significant health burden with an ever-increasing prevalence. They remain the leading causes of morbidity and mortality worldwide. The use of medicinal herbs continues to be an alternative treatment approach for several diseases including CVDs. Currently, there is an unprecedented drive for the use of herbal preparations in modern medicinal systems. This drive is powered by several aspects, prime among which are their cost-effective therapeutic promise compared to standard modern therapies and the general belief that they are safe. Nonetheless, the claimed safety of herbal preparations yet remains to be properly tested. Consequently, public awareness should be raised regarding medicinal herbs safety, toxicity, potentially lifethreatening adverse effects, and possible herb-drug interactions. Over the years, laboratory data have shown that medicinal herbs may have therapeutic value in CVDs as they can interfere with several CVD risk factors. Accordingly, there have been many attempts to move studies on medicinal herbs from the bench to the bedside, in order to effectively employ herbs in CVD treatments. In this review, we introduce CVDs and their risk factors. Then we overview the use of herbs for disease treatment in general and CVDs in particular. Further, data on the ethnopharmacological therapeutic potentials and medicinal properties against CVDs of four widely used plants, namely Ginseng, Ginkgo biloba, Ganoderma lucidum, and Gynostemma pentaphyllum, are gathered and reviewed. In particular, the employment of these four plants in the context of CVDs, such as myocardial infarction, hypertension, peripheral vascular diseases, coronary heart disease, cardiomyopathies, and dyslipidemias has been reviewed, analyzed, and critically discussed. We also endeavor to document the recent studies aimed to dissect the cellular and molecular cardio-protective mechanisms of the four plants, using recently reported in vitro and in vivo studies. Finally, we reviewed and reported the results of the

show abstract

Section: G Lucidum At the Bench: Mechanism Of Action In Cvdsmentioning

confidence: 90%

“…Bioactive/active fractions: By decreasing the levels of creatine phosphokinase (Hikino et al, 1985;Tomoda et al, 1986;Shi et al, 2002;Shi et al, 2010;Lasukova et al, 2015;Wang et al, 2015;Wihastuti and Heriansyah, 2017;Cuong et al, 2019;Wu et al, 2019)…”

Section: Ganoderma Lucidummentioning

confidence: 99%

Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Their computational protocol helped to explain that camel hemorphin had a higher binding affinity for ACE when compared to the mammalian one. In other work, Wu et al [27] identified three ACE inhibitory peptides, QLVP, QDVL, and QLDL, which account for the antihypertensive activity of Ganoderma lucidum, a polypore mushroom widely used in Asia to treat hypertension. They used docking and MD simulations to study the mode of action of the peptides.…”

Section: Molecular Modeling Applied To the Study Of Ace Inhibitors Inmentioning

confidence: 99%

Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors

Caballero

2020

Molecules

View full text Add to dashboard Cite

The angiotensin-converting enzyme (ACE) is a two-domain dipeptidylcarboxypeptidase, which has a direct involvement in the control of blood pressure by performing the hydrolysis of angiotensin I to produce angiotensin II. At the same time, ACE hydrolyzes other substrates such as the vasodilator peptide bradykinin and the anti-inflammatory peptide N-acetyl-SDKP. In this sense, ACE inhibitors are bioactive substances with potential use as medicinal products for treatment or prevention of hypertension, heart failures, myocardial infarction, and other important diseases. This review examined the most recent literature reporting ACE inhibitors with the help of molecular modeling. The examples exposed here demonstrate that molecular modeling methods, including docking, molecular dynamics (MD) simulations, quantitative structure-activity relationship (QSAR), etc, are essential for a complete structural picture of the mode of action of ACE inhibitors, where molecular docking has a key role. Examples show that too many works identified ACE inhibitory activities of natural peptides and peptides obtained from hydrolysates. In addition, other works report non-peptide compounds extracted from natural sources and synthetic compounds. In all these cases, molecular docking was used to provide explanation of the chemical interactions between inhibitors and the ACE binding sites. For docking applications, most of the examples exposed here do not consider that: (i) ACE has two domains (nACE and cACE) with available X-ray structures, which are relevant for the design of selective inhibitors, and (ii) nACE and cACE binding sites have large dimensions, which leads to non-reliable solutions during docking calculations. In support of the solution of these problems, the structural information found in Protein Data Bank (PDB) was used to perform an interaction fingerprints (IFPs) analysis applied on both nACE and cACE domains. This analysis provides plots that identify the chemical interactions between ligands and both ACE binding sites, which can be used to guide docking experiments in the search of selective natural components or novel drugs. In addition, the use of hydrogen bond constraints in the S2 and S2′ subsites of nACE and cACE are suggested to guarantee that docking solutions are reliable.

show abstract

“…The bioactive compounds are synthesized and secreted into the culture medium by the fermenting organisms during the process. SmF has been employed to ferment many food sources to obtain BPs, including cheese whey, mushroom, tomato pomace, and feather keratin (Mazorra-Manzano et al, 2020;Mechmeche et al, 2019;Moayedi et al, 2016Moayedi et al, , 2018Worsztynowicz et al, 2020;Wu et al, 2019). Several critical factors, including optimal operating conditions, substrates, and microorganisms used, should be considered during food fermentation for the production of BPs (Lasrado & Rai, 2018).…”

Section: Introductionmentioning

confidence: 99%

Bioactive peptides from food fermentation: A comprehensive review of their sources, bioactivities, applications, and future development

Chai

Voo

Chen

2020

Comp Rev Food Sci Food Safe

163

View full text Add to dashboard Cite

Bioactive peptides (BPs) are specific protein fragments that exert various beneficial effects on human bodies and ultimately influence health, depending on their structural properties and amino acid composition and sequences. By offering promising solutions to solve diverse health issues, the production, characterization, and applications of food-derived BPs have drawn great interest in the current literature and are of particular interest to the food and pharmaceutical industries. The microbial fermentation of protein from various sources is indubitably a novel way to produce BPs with numerous beneficial health effects. Apart from its lower cost as compared to enzymes, the BPs produced from microbial fermentation can be purified without further hydrolysis. Despite these features, current literature shows dearth of information on the BPs produced from food via microbial fermentation. Hence, there is a strong necessity to explore the BPs obtained from food fermentation for the development of commercial nutraceuticals and functional foods. As such, this review focuses on the production of BPs from different food sources, including the extensively studied milk and milk products, with emphasis on microbial fermentation. The structure-activity (antihypertensive, antioxidant, antimicrobial, opiate-like, anti-inflammatory, anticancer/antiproliferative, antithrombotic, hypolipidemic, hypocholesterolemic, and mineral binding) relationship, potential applications, future development, and challenges of BPs obtained from food fermentation are also discussed.

show abstract

Isolation and Characterization of Three Antihypertension Peptides from the Mycelia of Ganoderma Lucidum (Agaricomycetes)

Cited by 67 publications

References 48 publications

Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety

Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety

Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors

Bioactive peptides from food fermentation: A comprehensive review of their sources, bioactivities, applications, and future development

Contact Info

Product

Resources

About